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Abstract Somatostatin is a regulatory peptide with important
inhibitory functions. Its effects are mediated by five receptors,
sst1^sst5. Previous studies revealed that sst2 contains three
alternative, tissue specific promoters. Here, molecular mechan-
isms for the regulation of sst2 transcription by glucocorticoids
were investigated. Reporter gene assays in NG 108-15 cells and
electrophoretic mobility shift assays revealed that a glucocorti-
coid responsive element at position 31044 on the second
promoter mediates dexamethasone induction. These findings,
the existence of a cAMP response element and the tissue
dependent activity (brain, pituitary and gastrointestinal tissues)
indicate the importance of the second sst2 gene promoter.
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1. Introduction
Somatostatin acts as a potent inhibitor of endocrine and
exocrine secretions and neuronal functions and is involved
in various regulatory circuits in the central nervous system
and peripheral tissues. For example, somatostatin plays im-
portant roles in the pituitary as the physiological counterpart
of growth hormone releasing factor and within the gastroin-
testinal tract. There, it inhibits the release of many intestinal
peptides and pancreatic hormones and enzymes (reviewed in
[1]). In addition, stable analogs of somatostatin are used clin-
ically to treat tumors, because also growth of cancer cells is
inhibited by somatostatin action [2,3]. All these e¡ects are
mediated by ¢ve di¡erent somatostatin receptors (sst1^sst5)
[4^13]. In our laboratory we are focussing on the investigation
of the structure and the regulation of the sst2 gene (see Fig.
1). We have previously shown that this receptor subtype is
alternatively spliced at the 3P end resulting in the generation
of two isoforms (sst2A and sst2B) which di¡er within their C-
termini and exhibit di¡erent pharmacological properties
[13,14]. Furthermore, it was demonstrated that transcription
of the sst2 gene is initiated from three alternative promoters
which are active in a tissue and cell dependent manner [15].
Gene regulation studies revealed that these promoters are not
equally responsive to extracellular stimuli, as for instance to
agents that elevate the intracellular cAMP level [16]. Increas-
ing knowledge of such regulatory mechanisms may be of more
than academic interest since an adequate level of sst receptor
expression in cancer tissue is a prerequisite for an e¡ective
medical treatment with somatostatin analogs.
It is well known that glucocorticoids (GC) are involved in
the regulation and maintenance of physiological functions in
many systems. Among other functions, GC are also involved
in the ¢ne-regulation of somatostatin actions. It has been
reported that GC up- and downregulate gene expression of
the somatostatin gene itself [17,18], as well as somatostatin
receptor genes [19^21]. For example, it was demonstrated
that the number of sst receptors in certain brain areas in-
creased in response to GC [20]. At a cellular level it was
shown that mRNA levels of di¡erent sst subtypes as well
increase as decrease in pituitary GH4C1 cells in a time depend-
ent way [21]. Glucocorticoids are known to modulate gene
expression via an intracellular glucocorticoid receptor
(GCR). This, when activated, may function as a transcription
factor enhancing transcription or it may be directly involved
in the inhibition of transcriptional activity (reviewed in
[22,23]). This study reports attempts to reveal the molecular
basis for the transcriptional activation of the sst2 gene by
glucocorticoids.
2. Materials and methods
2.1. sst2 promoter constructs
The construction of the sst2 promoter-chloramphenicol acetyl
transferase reporter gene plasmids using the reporter gene vector plas-
mid system pBLCAT2/pBLCAT3 [24] is described in detail elsewhere
[16]. In addition to those plasmids, two reporter genes with internal
deletions of the second sst2 promoter were constructed as follows:
construct P2-1137 was ¢rst cut at two internal PstI sites at nt 3555
and 3593 and then digested with Bal31 enzyme. This digest was
stopped at di¡erent time points and the remaining plasmid was reli-
gated leading to the internal deletion constructs P2-1137del-968-232
and P2-1137del-1049-114. To yield construct G4.tk.CAT an oligonu-
cleotide (5P-GTTTTCTGATTTTTCATGTTCTAGAAACC-3P) was
inserted into the blunted BamHI site of pBLCAT2. All reporter plas-
mids were sequenced after construction.
2.2. Cell culture, transfections and CAT assays
NG 108-15 cells were cultured at 37‡C with 10% CO2 in Dulbecco’s
modi¢ed Eagle’s medium containing 10% fetal calf serum, 100 units/
ml penicillin, 100 mg/ml streptomycin with additional 0.1 mM hypo-
xanthin, 10 WM aminopterin and 17 WM thymidine. For transfections
106 cells were plated on 5 cm tissue culture dishes and allowed to
grow overnight. Medium was replaced and cells were transfected
with 8 Wg plasmid DNA using the method described by Chen and
Okayama [25]. After 16^18 h medium was renewed again and cells
were allowed to grow for 2 days in the presence of 1 WM dexametha-
sone or vehicle (ethanol) before harvesting. Harvesting and CAT ELI-
SA were performed according to the protocol of the CAT ELISA kit
from Boehringer Mannheim.
2.3. Extraction of nuclear protein
The nuclear protein extraction procedure of NG 108-15 cells for
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EMSA has been described in detail in a recent publication from this
laboratory [16].
2.4. Electrophoretic mobility shift assay
Synthetic oligonucleotides (Metabion, Martinsried) carrying puta-
tive GCR binding sites G1 to G5 were labeled with [Q-32P]ATP
(Amersham, Braunschweig) according to standard methods [26]. For
each band shift reaction 5000 cpm labeled probe DNA was incubated
with 3 Wl NG 108-15 cell nuclear extract for 60 min on ice in a 20 Wl
reaction mixture containing 10 mM Tris pH 7.5, 50 mM NaCl, 1 mM
DTT, 1 mM EDTA, 5% glycerol and 1 Wg poly(dIdC) DNA. Some
reactions also contained various amounts of competitor DNA. For
immunoshift experiments nuclear extract was preincubated with 3 Wg
GCR antibody (‘P-20’, Santa Cruz Biotechnology, Heidelberg). Sam-
ples were loaded onto 6% polyacrylamide gels and separated electro-
phoretically. The gels were then dried and exposed to Kodak XO-
MAT AR ¢lms. Sequences of the oligonucleotides were: classical
GRE: 5P-AGGATCTGTACAGGATGTTCTAGATCG-3P, G1: 5P-
CACACAGACACGTGTGTGCTTACTC-3P, G2: 5P-CCCCCAGA-
GGAGACTGTACCTTCGCA-3P, G3: 5P-CTGCCACGGCTGACC-
TGTCCACCAGGT-3P, G4: 5P-GTTTTCTGATTTTTCATGTTC-
TAGAAACC-3P, G5: 5P-CTGACTCTGCAACCTGTGCCCTGTT-
CCCCG-3P.
2.5. Statistical analysis
For statistical evaluation student’s t-tests were performed. Asterisks
(*) indicate signi¢cant di¡erent values (P6 0.05).
3. Results
3.1. The second sst2 promoter may be stimulated by
glucocorticoids
We have recently published the structure of the sst2 gene
upstream regulatory region and sequences of the three sst2
promoters [15]. Searching for putative binding sites for the
glucocorticoid receptor (GCR), ¢ve DNA stretches, termed
G1^G5, were found within these sequences. Requirements
were that these sequences (a) share at least a homology of
60% with the classical GRE consensus sequence and (b) con-
tain the core sequence 5P-TGTNC-3P at the 3P half of the
imperfect palindromic classical GRE. The T residue at the
12th position distinguishes GRE elements from similar puta-
tive estrogen receptor binding sites [22,23]. The putative sst2
GRE elements and the classical GRE sequence are shown in
Table 1. To investigate a possible role of these elements in
activation of transcription of the sst2 gene in response to GC
transfection experiments were carried out (Fig. 2). For this
purpose various chloramphenicol acetyl transferase reporter
gene constructs containing parts of the three sst2 promoters
were made. These constructs were tested in transiently trans-
fected NG 108-15 cells (a neuroblastomaUglioma hybrid cell
line) for their ability to respond to dexamethasone treatment.
As controls reporter plasmids containing the thymidine kinase
promoter of the herpes simplex virus (pBLCAT2 [24]) were
used. The basal transcriptional rate of these constructs in NG
108-15 cells has been already described elsewhere [16]. Con-
struct P1-425 which carries sequences of the ¢rst sst2 pro-
moter (lane 1) did not confer dexamethasone responsiveness
Fig. 1. Structure of the mouse somatostatin receptor type 2 gene.
The schematic drawing of the genomic organization (top) shows in-
tronic sequences as lines and exons as boxes. The protein coding se-
quence is hatched. The ¢rst two introns are longer than 25 kb. The
gene consists of four exons, two of which are located within the un-
translated upstream region of the gene. The fourth exon is divided
in two parts (4a and 4b), which are alternatively spliced. The sst2
gene contains three promoters (P1^P3); the transcription initiation
sites are indicated as arrows. The second promoter contains a cyclic
AMP response element (CRE) shown as a small box. Below: Six
di¡erent mRNA transcripts are possible for sst2. Transcripts may
derive from either of the three promoters and each transcript may
contain exon 4a or 4b. The latter alternative leads to the generation
of two receptor protein variants (sst2A and sst2B) with di¡erent
carboxy-terminal tails.
Fig. 2. Transient expression of reporter gene constructs in NG 108-15 cells. On top, a schematic drawing shows the three sst2 promoters with
the relative location of the ¢ve putative GC responsive elements G1 to G5 (open ovals). Exons are shown as boxes and transcriptional start
sites as arrows. Below, the results of the transfection experiments are shown. Left, the reporter gene plasmids with sst2 promoter sequences are
indicated relative to their position within the gene. Right, CAT activities for the respective constructs are expressed as fold induction for dexa-
methasone (1 WM) treated transfected cells (grey bars) compared to vehicle treated transfected cells (white bars).
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although it contains three out of the ¢ve putative GRE se-
quences of the gene (G1, G2, G3). The longest construct with
sequences of the second promoter, which contains the remain-
ing two putative GREs, G4 and G5, showed a signi¢cant 2.0-
fold stimulation after dexamethasone treatment of transfected
cells (construct P2-1137, lane 2). Deletions of promoter 2 se-
quences up to nt 3562 (construct P2-562, lane 3) and 3437
(construct P2-437, lane 4) both abolished the stimulatory ef-
fect. Since construct P2-562 lacks G4 but still contains G5, it
is suggested that G4 may mediate the dexamethasone e¡ect.
To test this hypothesis we constructed two additional reporter
plasmids with internal deletions which contain G4 or do not.
The G4 containing construct showed a signi¢cantly 1.6-fold
dexamethasone stimulated reporter gene expression (construct
P2-1137del-968-232, lane 5), whereas the deletion construct
which lacks G4 showed no stimulation (construct P2-
1137del-1045-114, lane 6). The sequences of the third sst2
promoter tested in this study were not responsive to dexa-
methasone (construct P3-567, lane 7). To test if the G4 se-
quences alone are su⁄cient to mediate dexamethasone in-
duced reporter gene expression a 29-mer oligonucleotide
containing G4 and adjacent sequences was cloned in the
pBLCAT2 plasmid upstream of the tk promoter (construct
G4.tk.CAT, lane 9). Transfection experiments showed a sig-
ni¢cant 1.9-fold stimulation with this reporter plasmid com-
pared with vehicle treated controls.
3.2. Glucocorticoid receptor binds to a GRE within the second
sst2 promoter
The ¢ve putative GRE elements of the sst2 gene were then
subjected to electrophoretic mobility shift assays to investigate
binding of nuclear proteins (Fig. 3). Incubation of a radio-
actively labeled classical GRE oligonucleotide with NG 108-
15 nuclear extract (Fig. 3A, lane 1) resulted in a typical pat-
tern of several shifted bands: a double band on top of the gel
(A), two faster migrating bands (B and C) and additionally
two unspeci¢c (see below) bands (U). In the following the
speci¢city of the shifted complexes was studied using various
non-labeled competitor oligonucleotides. Using classical GRE
Table 1
Putative glucocorticoid response elements on the sst2 gene pro-
moters
Putative
element
sst2
promoter
Position Sequence
G1 1 3378 5P-AGACACGTGTGTGCT-3P
G2 1 3303 5P-AGAGCAGACTGTACC-3P
G3 1 3262 5P-CGGCTGACCTGTCCA-3P
G4 2 31044 5P-GATTTTTCATGTTCT-3P
G5 2 3488 5P-TCTGCAACCTGTGCC-3P
GRE consensus 5P-GGTACANNNTGTYCT-3P
The sequences of the ¢ve elements G1^G5 which are similar to the
classical glucocorticoid response element (GRE) are shown along
with their location with respect to the transcription initiation site of
the respective promoter.
6
Fig. 3. Electrophoretic mobility shift assays of the putative sst2
GRE motifs. The tables above the autoradiograms give the compo-
sition of the reactions: the lower panel designates the probe that
was used in the experiment and the upper panel shows which com-
petitor DNA or antibody was used. Abbreviations are: cl. GRE,
oligonucleotide with consensus sequence of a classical GRE; Ab,
antibody against GCR protein; G1 to G5, oligonucleotides with se-
quences of the putative sst2 elements. Competitor DNA was used in
5- and 25-fold molar excess as indicated schematically. Nuclear ex-
tract was isolated from NG 108-15 cells. The arrows mark the posi-
tion of speci¢c (A, B, C) and unspeci¢c (U) complexes and the free
probes (P).
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competitor the intensity of speci¢c bands decreased (lanes 2
and 3). Similar, immunoprecipitation of GCR protein prior to
the bandshift reaction by preincubation of nuclear extract
with a speci¢c antibody resulted in a drastic decrease in in-
tensity of the speci¢cally shifted complexes (lane 4). When
G1^G5 oligonucleotides were used to compete for the classical
GRE probe (lanes 5 to 14) only G4 oligonucleotides were as
e¡ective as the classical GRE competitor (lanes 11 and 12,
compare lanes 2 and 3). Fig. 3B shows the bandshift analysis
of the G4 oligonucleotide. Incubation of G4 with nuclear
extracts resulted essentially in the same shift pattern as the
classical GRE with the exception that band C was only very
weak (lane 1). Bands A and B were also recognized by the
glucocorticoid receptor antibody, indicating that G4 binds the
GCR (lane 2). This is supported by the fact that classical
GRE oligonucleotides e⁄ciently competed for binding to G4
(lanes 3 and 4). When using G1^G3 and G5 oligonucleotides
as probes (Fig. 3C) either shift patterns that were di¡erent
from the classical GRE pattern appeared for G1 (lanes 1 to
3), G3 (lanes 7 to 9) and G5 (lanes 10 to 12) or no binding at
all was observed as for G2 (lanes 4 to 6). Furthermore, the
shifted bands of G1, G3 and G5 could only negligible be
competed by the classical GRE sequences, indicating that
other proteins than GCR bind to these sequences. Bands U
are regarded as unspeci¢c since they are either competed by
all oligonucleotides in higher concentrations (the upper one)
or there is no apparent competition at all (the lower one).
4. Discussion
The somatostatin receptor 2 gene is regulated by glucocor-
ticoids in vivo, however, the molecular mechanisms underly-
ing this process are still largely unknown. Thus, in an early
study it was shown that adrenalectomy in rats causes a de-
crease of somatostatin receptors in certain brain areas, which
could be normalized again by GC replacement [20]. In anoth-
er study the e¡ect of the synthetic GC dexamethasone on sst2
mRNA levels in the pituitary cell line GH4C1 was presented
earlier by Xu and colleagues [21]. Using mRNA hybridization
techniques the authors showed that dexamethasone ¢rst,
measured after 2 h, leads to an about 1.6-fold increase in
sst2 mRNA levels, which was followed by a decrease in
mRNA levels within 24 h. Measured at 48 h sst2 mRNA
levels showed a tendency to increase again. Nuclear run-on
assays and experiments in which the half life of sst2 mRNA
was measured lead the authors to the conclusion that the
e¡ects of dexamethasone are mainly due to changes in the
transcription rate of the sst2 gene and not to changes in
mRNA stability.
In general, regulation of gene expression by GC involves
various mechanisms which may lead to either activation or
inhibition of target gene transcription [22,23]. Inhibition of
transcription includes mechanisms such as (a) direct protein-
protein interactions between GCR and stimulatory transcrip-
tion factors, (b) competitive binding of GCR and stimulatory
factors to regulatory DNA elements and (c) interaction of
GCR with negative regulatory DNA elements within gene
promoters. Stimulation of gene expression by GC is known
to be mediated via cis-acting promoter elements termed glu-
cocorticoid response elements (GREs). These are conserved
binding sites for the hormone activated GCR, which when
bound acts as a factor enhancing transcription [27]. A com-
plex regulation process as it is found for the sst2 gene and
GC, which consists of several phases with increasing as well as
decreasing mRNA levels, may result from combined inhibi-
tory and stimulatory mechanisms. In this report we present
molecular mechanisms which can explain the GC induced in-
crease in sst2 mRNA levels. In particular, promoter sequences
were identi¢ed, which might serve as functional GRE se-
quences. Out of ¢ve potential GRE sequences, which are
found on the three sst2 promoters (G1^G5), one, namely
G4, was shown to constitute a functional GRE. This element
is located on the second promoter at position 31044 with
respect to its transcription initiation site. It is also active in
front of the heterologous viral herpes simplex thymidine ki-
nase promoter, where a 29-mer oligonucleotide containing G4
and adjacent sequences was su⁄cient to confer GC stimula-
tion in transiently transfected NG 108-15 cells. Similar to the
increase in sst2 mRNA in GH4C1 cells discussed above an
induction rate of 1.6- to 2-fold was observed in our trans-
fection experiments with the sst2 promoter reporter con-
structs. Gel retardation experiments and immunoshift experi-
ments revealed almost identical nuclear protein binding
patterns for G4 and a classical GRE. Taken together, the
results presented here convincingly indicate that the sst2
gene contains a functional GRE on its second promoter.
The other two sst2 promoters did not respond to GC and
do not contain GRE sequences. The putative GREs G1^G3
and G5 displayed completely di¡erent nuclear protein binding
properties in the gel retardation experiments compared to the
classical GRE and G4.
Astonishingly, incubation of transfected cells with dexa-
methasone did lead in no case to an inhibition of reporter
gene expression. If mainly transcriptional changes should be
responsible also for the decrease of sst2 mRNA, as suggested
by Xu and colleagues [21], it must be assumed that other
promoter sequences are responsible. These may either be lo-
cated further upstream of the sequences isolated so far, or on
an additional promoter.
The existence of a functional GRE on the second sst2 pro-
moter emphasizes its importance for the transcriptional regu-
lation of the gene. Thus, the second promoter also contains a
functional cyclic AMP responsive element, whereas the ¢rst
and the third do not [16]. Furthermore, the second promoter
is active in those tissues in which somatostatin has key func-
tions (brain, pituitary and gastrointestinal tissues) [15]. The
use of alternative promoters is being recognized as a mecha-
nism creating £exibility and diversity in gene expression in a
growing number of genes (for a review see [28]). Alternative
transcripts may lead to protein variants of the same gene, as it
is the case for the sst2 gene within the carboxy-terminal region
[13]. Furthermore, alternative transcripts of one gene may be
active in di¡erent tissues [29], or responsive in di¡erent ways
to extracellular and hormonal stimuli [30]. These two possi-
bilities are also realized in the sst2 gene. This has the conse-
quence that a regulatory stimulus is only e¡ective in these cells
and tissues that use the promoter equipped with the regula-
tory elements. Interestingly, it was found by Rodriguez et al.
[20] that a GC regulation of somatostatin receptors occurred
only in certain brain areas although they are expressed in all
of the areas which were studied. Alternative promoter usage
and thus alternative responsiveness may be an explanation for
this. Therefore, both knowledge of tissue and cell speci¢c
promoter usage and localization of regulatory elements is
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needed to understand the complexities of sst2 gene expression.
More important than just understanding sst2 gene regulation
may be the possibility to use stimulatory regulators in order to
increase the number of sst2 receptors on certain tumor cells.
This could have an additive e¡ect to that of stable somato-
statin analogs, which already are used clinically to treat cer-
tain tumors.
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